|Bid||110.00 x 800|
|Ask||116.88 x 1100|
|Day's Range||114.13 - 116.30|
|52 Week Range||53.21 - 133.96|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Sohn Conference is my favorite hedge fund event. I haven't missed an event since 2013. This doesn't mean that every stock pitched at the conference is a great investment opportunity and will beat its benchmark. A few weeks ago we took a look at the performance of the stocks pitched at the 2018 Sohn Conference […]
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ascend...
Is Ascendis Pharma A/S (NASDAQ:ASND) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Glenview Capital Management is a New York City-based hedge fund, that was launched 18 years ago by Larry Robbins, who previously worked as a trader for billionaire Leon Cooperman’s Omega Advisors. The fund posted return of 301% after fees and expenses for the first decade of its existence, even though 2008 posed too many difficulties […]
Harvest Capital Strategies is a San Francisco-based hedge fund that mainly focuses on private equity and venture capital, middle-market lending and on equity hedge funds. It was founded back in 1999, and it operates as a subsidiary of JMP Group Inc. Joseph Jolson, the fund’s CEO, co-founded JMP Group and is its CEO and the […]
Read the beginning of this article here. Nathaniel August recommended a position in Peabody Energy (NYSE:BTU) which “is the largest and least expensive way to participate in the coal market” according to this fund manager. Unfortunately the stock lost more than 26% since August’s recommendation. David Einhorn recommended a short position in Assured Guaranty (NYSE:AGO) due […]
It has been almost a year since the last annual Sohn Conference held in New York, and we thought it would be interesting to take a look at how some of the stock pitches presented there have performed since. Today, we are going to take a look at Light Street’s Glen Kacher’s best idea from […]
Nathaniel August’s Mangrove Partners is known for outperforming the market very often; in the first three years since its launching (2010), the fund brought an astonishing return of 44% annually. It continued with its strong performance in the next year, delivering 26.6%. In spite of losing around 1.9% in 2015, the fund compensated for it […]
Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%. Just for the comparison, an average activist hedge fund reported a loss of 11% in the same period, and the S&P 500 lost 4.4%. Even over the last three years, the fund […]
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
This is how we shared Jeff Ubben's CBRE Group Inc (NYSE:CBRE) stock pitch more than 6 years ago: "On October 2, 2012, ValueAct Capital‘s fearless leader Jeffrey Ubben made a presentation on Day 2 of the 8th Annual Value Investing Congress in New York. Entitled “Avoiding Complexity and the VAC Circle of Life”, Ubben discussed several aspects of […]
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards canRead More...
Ascendis Pharma A/S (NASDAQ: ASND ) announced the pricing of its underwritten public offering of 4,166,667 American Depositary Shares ("ADSs"), each of which represents one ordinary share of ...
Why Ascendis Pharma Is Soaring TodayShare price movementToday, Ascendis Pharma (ASND) is trading close to $112.17, which is 61.8% higher than its previous closing price. The company’s market capitalization is $2.94 billion.Ascendis released a
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]